Dizal Pharmaceuticals

This phase 2 trial is testing a combination of two oral drugs, DZD8586 and venetoclax, in people with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have not yet been treated. The study will first check safety, then see if the combination can keep the ca…

This Phase 3 trial tests a new drug, golidocitinib, against standard treatments for adults with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer. About 218 participants worldwide will receive either golidocitinib pills or a doctor-chosen drug. The goal is to…

This study tests a new drug called DZD8586 against standard treatments in 250 adults whose chronic lymphocytic leukemia or small lymphocytic lymphoma has come back or stopped responding to prior therapy. The main goal is to see if DZD8586 can delay cancer growth longer than the d…

This study tests an experimental drug called DZD8586 (Birelentinib) in 155 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or not responded to prior treatment. Participants take one of three daily doses to see if the drug shrinks tumors an…

This study tests a combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose; the second part compares the combo to standard chemotherapy. About 165 adults with newly diagnosed or relapsed disease will take part. The…

This study tests a new drug called DZD8586 combined with standard treatments for diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. It involves 150 adults whose cancer is either newly diagnosed or has returned after initial therapy. The goal is to see if the comb…

This early-stage trial is testing a new daily pill called DZD6008 in 140 people with advanced non-small cell lung cancer that has certain EGFR mutations. The main goals are to check the drug's safety and see if it can shrink tumors. Participants will take DZD6008 by mouth every d…

This study tests a new drug called GW5282 in people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 203 adults will take part in this early-phase trial.

This phase 2 trial tests an experimental oral drug called DZD8586 (Birelentinib) in adults with primary immune thrombocytopenia (ITP) whose condition did not improve after at least one standard therapy. About 60 participants will receive one of three dose levels to see if it safe…

This study tests two experimental drugs, DZD9008 and AZD4205, together in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard treatments. About 90 adults will take part to see if the combination is…

This early-stage trial tests a new drug called DZD6008 in about 190 people with advanced non-small cell lung cancer that has a specific EGFR mutation. The main goals are to check the drug's safety and see if it can shrink tumors. Because this is the first time the drug is given t…